- Home
- ROL vs BIIB Comparison
ROL vs BIIB Comparison
Compare ROL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROL
- BIIB
- Stock Information
- Founded
- ROL 1948
- BIIB 1978
- Country
- ROL United States
- BIIB United States
- Employees
- ROL N/A
- BIIB N/A
- Industry
- ROL Diversified Commercial Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ROL Finance
- BIIB Health Care
- Exchange
- ROL Nasdaq
- BIIB Nasdaq
- Market Cap
- ROL 27.6B
- BIIB 18.8B
- IPO Year
- ROL N/A
- BIIB 1991
- Fundamental
- Price
- ROL $55.34
- BIIB $135.28
- Analyst Decision
- ROL Buy
- BIIB Buy
- Analyst Count
- ROL 8
- BIIB 27
- Target Price
- ROL $58.75
- BIIB $188.17
- AVG Volume (30 Days)
- ROL 1.6M
- BIIB 1.2M
- Earning Date
- ROL 07-23-2025
- BIIB 07-31-2025
- Dividend Yield
- ROL 1.19%
- BIIB N/A
- EPS Growth
- ROL 9.41
- BIIB 26.39
- EPS
- ROL 0.99
- BIIB 10.12
- Revenue
- ROL $3,462,863,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- ROL $11.84
- BIIB N/A
- Revenue Next Year
- ROL $8.58
- BIIB N/A
- P/E Ratio
- ROL $56.32
- BIIB $13.29
- Revenue Growth
- ROL 9.46
- BIIB 1.59
- 52 Week Low
- ROL $45.34
- BIIB $110.04
- 52 Week High
- ROL $58.65
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- ROL 41.53
- BIIB 61.69
- Support Level
- ROL $54.97
- BIIB $129.08
- Resistance Level
- ROL $56.94
- BIIB $134.75
- Average True Range (ATR)
- ROL 0.94
- BIIB 3.74
- MACD
- ROL -0.14
- BIIB 0.65
- Stochastic Oscillator
- ROL 14.07
- BIIB 82.50
About ROL Rollins Inc.
Rollins is a global leader in route-based pest control services, with operations primarily in the United States, as well as in North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US, which boasts near national coverage, and in Canada. Residential pest and termite prevention dominates the services provided by Rollins, owing to the group's ongoing focus on the US and Canadian markets.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.